CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.07M, lower than 95% of all stocks globally
- PositionReturn on equity is -373.3%, lower than 95% of its Biotechnology peers (median -22.3%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
526.90MUSDvs all stocks (USD)
Revenue (TTM)
4.07MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.35xvs all stocks
52-Week Change
-45.49%vs all stocks
Market Capitalization
526.90MUSDvs all stocks (USD)
Enterprise Value
533.33MUSDvs all stocks (USD)
Forward P/E
-3.27xvs Biotechnology peers
Price to Book (MRQ)
12.89xvs Biotechnology peers
Enterprise to Revenue
130.94xvs Biotechnology peers
Enterprise to EBITDA
-2.82xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-3750.87%vs Biotechnology peers
Return on Assets (TTM)
-46.52%vs Biotechnology peers
Return on Equity (TTM)
-373.29%vs Biotechnology peers
Revenue (TTM)
4.07MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0240USDUpdated Sep 28, 2026Quarterly Revenue Growth
3.50%vs Biotechnology peers
Gross Profit (TTM)
-142.13MUSDvs all stocks (USD)
EBITDA (TTM)
-189.12MUSDvs all stocks (USD)
Net Income (TTM)
-187.89MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.50%vs Biotechnology peers
Operating Cash Flow (TTM)
-156.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-75.78MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.63MUSDFY2025 · Dec 31, 2025Operating Income
-208.35MUSDvs all stocks (USD)
Pre-tax Income
-201.14MUSDFY2025 · Dec 31, 2025Net Income
-201.14MUSDFY2025 · Dec 31, 2025EBIT
-208.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-201.46MUSDFY2025 · Dec 31, 2025Research & Development
160.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.35MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.15MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-201.14MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-163.58MUSDFY2025 · Dec 31, 2025Free Cash Flow
-168.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
76.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-201.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
7.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.27MUSDFY2025 · Dec 31, 2025Other Non-cash Items
9.70MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
996.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.53MUSDFY2025 · Dec 31, 2025Purchase of Investments
-205.41MUSDFY2025 · Dec 31, 2025Sale of Investments
101.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-108.76MUSDFY2025 · Dec 31, 2025Other Financing Charges
12.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
150.39MUSDFY2025 · Dec 31, 2025Shares Outstanding
180.74MSharesUpdated Sep 28, 2026Float Shares
112.25MSharesUpdated Sep 28, 2026Shares Short
32.13MSharesUpdated Sep 28, 2026Short Ratio
11.74daysvs all stocks
Short % of Shares Outstanding
22.65%vs all stocks
% Held by Insiders
23.66%vs all stocks
% Held by Institutions
70.97%vs all stocks
Total Cash (MRQ)
95.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5340USDUpdated Sep 28, 2026Total Debt (MRQ)
112.48MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.83xvs Biotechnology peers
Current Ratio (MRQ)
3.06xvs Biotechnology peers
Book Value per Share (MRQ)
0.2250USDUpdated Sep 28, 2026Total Assets
342.73MUSDvs all stocks (USD)
Total Current Assets
181.29MUSDFY2025 · Dec 31, 2025Total Liabilities
221.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
161.44MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
184.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
37.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.03MUSDFY2025 · Dec 31, 2025Other Short-term Investments
114.65MUSDFY2025 · Dec 31, 2025Accounts Payable
8.89MUSDFY2025 · Dec 31, 2025Short-term Debt
8.14MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.82MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.70MUSDFY2025 · Dec 31, 2025Long-term Debt
108.29MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-888.35MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
120.87MUSDvs all stocks (USD)
52-Week Low
2.67USDUpdated Sep 28, 202652-Week High
6.94USDUpdated Sep 28, 202652-Week Change
-45.49%vs all stocks
Beta
2.35xvs all stocks
50-Day MA
3.24USDUpdated Sep 28, 2026200-Day MA
3.52USDUpdated Sep 28, 2026Avg 10-Day Volume
3.60MSharesUpdated Sep 28, 2026Avg 30-Day Volume
3.03MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.05USDUpdated Sep 28, 2026Other Income / Expense
3.06MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -373.3%, lower than 95% of its Biotechnology peers (median -22.3%)Significant
Return on equity: -3.73Industry median: -0.22Industry P5: -1.57Peers compared: 260
Debt-to-equity is 2.83×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 2.83Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 95,071,000Total Debt (USD): 112,478,000Debt-to-Equity: 2.83
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.06Altman Z-Score: -3.69
Financial Health
Altman Z-Score -3.69: distress zoneCritical
Altman Z-Score: -3.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.07M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,073,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Cerus Corporation
Tier 1ProductionApproval-Gated PipelineRule
Senseonics Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eupraxia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pulike Biological Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated